Qian-Qian Wang

Qian-Qian Wang

Auto-generated profile, based on publicly available information

Qian-Qian Wang

Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2023 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
QWQian-Qian Wang
Qian-Qian Wang
CTChang Tan
Chang Tan
GQGeng Qin
Geng Qin
SYShu-Kun Yao
Shu-Kun Yao
Gastrointestinal cancer is one of the most malignant tumors with high morbidity and mortality, especially colorectal cancer, which has become the second leading cause of cancer-related deaths worldwide. Targeted drug treatment and precise endoscopic resection can significantly improve the overall survival rate and greatly extend the life span. Promising biomedical applications of hydrogels would represent hopeful therapeutic alternatives for patients with different kinds of diseases, particularly providing precise therapy for cancer patients. Although the intersection field of material science and biomedical science has made tremendous advances, major challenges remain. In this review, the application of hydrogel-based technology in cancer precision medicine is the focus of attention, which is the development trend of multidisciplinary cooperation in the future. First, we provide the current clinical landscape of hydrogel applications, and then we highlight precision oncology, including personalized drug treatment and accurate endoscopic intervention. Finally, we discuss major challenges for their clinical translation that have not yet been overcome and future perspectives on cancer precision medicine.

4 January 2023 in Endoscopy
Verified
Journal Article
Open access
PDF file
GQGeng Qin
Geng Qin
QWQian-Qian Wang
Qian-Qian Wang
CTChang Tan
Chang Tan
Endoscopic submucosal dissection (ESD) is an effective treatment for early-stage gastrointestinal cancer [1] [2]. However, difficult site lesions (e. g., colon flexion, right-side colon) and large mucosal defects (greater than 5 cm) result in post-ESD defect closures as an ongoing challenge in clinical practice [3]. Therefore, we report a novel method for the efficient closure of large mucosal defects after ESD using nylon loops combined with titanium clips. We demonstrate the application of this method in a real case of post-ESD large defect closure ([Video 1]). An 80-year-old man was found to have a circumferential 1/3 perineal lateral developmental tumor in the left posterior wall of the rectum 4–7 cm from the anal orifice with a pathology of high-grade intraepithelial neoplasia. The operation procedure was as follows. After complete debridement of the lesion by ESD ([Fig. 1]), one titanium clip with a nylon loop was fixed at the midpoint of one side of the incision margin ([Fig. 2]). Another titanium clip was fixed at the midpoint of the opposite side of the incision margin ([Fig. 3]), and then the nylon loop was gathered to transform the oval-shaped defect into a “figure-eight-shaped” defect ([Fig. 4]). The remaining defect was closed with an appropriate amount of additional titanium clips. Video 1 The application of nylon loop combined with titanium clips in a real case of large mucosal defect closure after endoscopic submucosal dissection. This method was applied to 50 patients with lesions ranging from 1/3–1/2 of the circumference of the bowel, and the mean closure time was 12.6 minutes. The mean number of titanium clips was 7.4, saving endoscopic closure time and the number of titanium clips compared to previous studies [4]. In addition, based on this, we have further developed a combination device consisting of a titanium clip and multiple nylon rings ([Fig. 5]), for which a patent application has been submitted in China. The device can further reduce the endoscopic closure time to 7 minutes, significantly improving the efficiency of endoscopic closure of large mucosal defects. Endoscopy_UCTN_Code_TTT_1AQ_2AD Article published online: 27 June 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

21 November 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
SZShuai Zhang
Shuai Zhang
QWQianqian Wang
Qianqian Wang
HXHaoran Xia
Haoran Xia
HLHui Liu
Hui Liu
Acute myeloid leukemia (AML) is a malignant hematological malignancy with a poor prognosis. Risk stratification of patients with AML is mainly based on the characteristics of cytogenetics and molecular genetics; however, patients with favorable genetics may have a poor prognosis. Here, we focused on the activity changes of immunologic and hallmark gene sets in the AML population. Based on the enrichment score of gene sets by gene set variation analysis (GSVA), we identified three AML subtypes by the nonnegative matrix factorization (NMF) algorithm in the TCGA cohort. AML patients in subgroup 1 had worse overall survival (OS) than subgroups 2 and 3 ( ). The median overall survival (mOS) of subgroups 1–3 was 0.4, 2.2, and 1.7 years, respectively. Clinical characteristics, including age and FAB classification, were significantly different among each subgroup. Using the least absolute shrinkage and selection operator (LASSO) regression method, we discovered three prognostic gene sets and established the final prognostic model based on them. Patients in the high-risk group had significantly shorter OS than those in the low-risk group in the TCGA cohort ( ) with mOS of 2.2 and 0.7 years in the low- and high-risk groups, respectively. The results were further validated in the GSE146173 and GSE12417 cohorts. We further identified the key genes of prognostic gene sets using a protein-protein interaction network. In conclusion, the study established and validated a novel prognostic model for risk stratification in AML, which provides a new perspective for accurate prognosis assessment.

8 January 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CTChang Tan
Chang Tan
QWQian-Qian Wang
Qian-Qian Wang
YZYuanchen Zhou
Yuanchen Zhou
GQGeng Qin
Geng Qin
SYShu-Kun Yao
Shu-Kun Yao
Background Advanced colorectal adenomas are precancerous lesions of colorectal cancer (CRC), and early screening and diagnosis are highly important for improving patient prognosis. However, traditional blood tumor markers have poor diagnostic efficacy for advanced adenoma (AA) and early-stage CRC. Methods We collected serum samples from normal controls, AA patients, and CRC patients (before and 48 h after surgery). Using the enzyme-linked immunosorbent assay method, we compared the serum lipopolysaccharide-binding protein (LBP) and vasodilator-stimulated phosphoprotein (VASP) levels among the three groups. Additionally, we analyzed and compared the serum LBP and VASP levels with the clinicopathological features of the tumors. Finally, we plotted receiver operating characteristic curves, calculated the area under curve and cutoff points, and evaluated the diagnostic efficacy of serum LBP and VASP for AA and CRC patients. Results Serum LBP and VASP levels were significantly greater in patients with AA and CRC than in healthy controls, and decreased significantly postoperatively compared with preoperatively. Compared with clinicopathological features, serum LBP levels were significantly greater in patients with severe dysplasia in adenomas, whereas serum VASP levels were significantly greater in patients with larger tumors, advanced stages, poorer tumor differentiation, and KRAS gene mutations. Compared with traditional tumor markers, serum LBP and VASP demonstrate good diagnostic efficacy for AA and CRC. Conclusion Our study innovatively proposes that the serum LBP and VASP proteins could serve as potential novel biomarkers for noninvasive screening of colorectal tumors, with better diagnostic efficacy than traditional blood tumor markers.